tbuckley/cabot-search huggingface dataset:
FRI0221 More Health for Lower Costs – Data from Two Clinics Treating RA in 2012-13: Table 1
Authors: T. Sokka-Isler, G. Haugeberg, T. Rannio, I.J. Widding Hansen, D.M. Soldal, J. Asikainen, P. Hannonen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Biologic drugs have improved outcomes of RA. However, many health care systems do not afford biologic drugs, and conventional DMARDs have to be used effectively including combinations. It was demonstrated in 2010 that good clinical outcomes of RA did not require wide use of biologics (Sokka et al CER 2013). <h3>Objectives</h3> To compare clinical outcomes, medications, and medication costs of patients with RA in two rheumatology clinics with different traditions of DMARD use. <h3>Methods</h3> Cross sectional observational clinical data of all patients with RA seen in 2012-13 in two rheumatology clinics, which both served a population of about 275,000. Clinical characteristics, disease activity, patient self-reported outcomes, and medications of the most recent visit were compared between the clinics using student9s T-test, Chi Square, and nonparametric tests. Annual costs of medications to the society were calculated per 100 patients, using an assumption that a patient is taking current medications for one year. <h3>Results</h3> Patient populations (n=1230 in Clinic1=C1 and 1495 in Clinic2=C2) were similar according to age (63 vs 62yr), gender (68-70%F), disease duration, and prevalence of seropositivity (Table 1); smoking habits were different (22% vs 13%). Disease activity was low and patients9 functional status well reserved in both clinics. Remission criteria were met by 51% and 64% of patients. Biologic drugs were used more frequently in Clinic1 by 32.8% vs Clinic2 by 19.6% of patients while a combination of conventional anti-rheumatic drugs was used by &lt;1% and 41%, respectively. Estimated annual costs of medications per 100 patients were €501,000 and €270,000. <h3>Conclusions</h3> Data are confirmatory to previous observations that remission/low disease activity and good functional status can be reached in RA using expensive and less-expensive anti-rheumatic drugs, in 2012-13. Therefore, treating 1000 RA patients a year leads to 2.3 million Euros expenses/savings in medications, depending of what medications are used, without compromising outcomes including disease activity and patient reported outcomes. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2604
Unintended Consequences — The Cost of Preventing Preterm Births after FDA Approval of a Branded Version of 17OHP
Authors: Joanne Armstrong
Journal: New England Journal of Medicine (2011)

The recent approval by the Food and Drug Administration of Makena, a new version of progesterone 17 alpha-hydroxyprogesterone caproate, will drive up the drug's cost about 100-fold, with minimal added clinical benefit.
Undercounting of football concussions skewed NFL research, US investigation alleges
Authors: Michael McCarthy
Journal: BMJ (2016)

Research by a National Football League (NFL) committee that found that head trauma had posed no significant risk to professional football players was skewed by significant undercounting of the number of concussions that the athletes had experienced, the New York Times reported on 24 March.1

The reporters found that, although the NFL committee members had claimed in their papers that they had included all concussions diagnosed by team medical staff from 1996 to 2001 in their analysis (887 in total), more than 100 concussions were not included.

Most …
Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma
Authors: Alan Ka‐Lun Kai, Lo Kong Chan, Regina Cheuk‐Lam Lo, Joyce Man‐Fong Lee, Carmen Chak‐Lui Wong, Jack Chun‐Ming Wong, Irene Oi‐Lin Ng
Journal: Hepatology (2016)

Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (H epatology 2016;64:473‐487)
Guideline Familiarity Predicts Variation in Self-Reported Use of Routine Surveillance PET/CT by Physicians Who Treat Head and Neck Cancer
Authors: Benjamin R. Roman, Snehal G. Patel, Marilene B. Wang, Anna M. Pou, F. Christopher Holsinger, David Myssiorek, David Goldenberg, Samuel Swisher-McClure, Alexander Lin, Jatin P. Shah, Judy A. Shea
Journal: Journal of the National Comprehensive Cancer Network (2015)

Background: Use of routine surveillance testing beyond guideline recommended levels is common in many oncologic disciplines, including head and neck cancer. The impact of guideline familiarity and other physician characteristics on surveillance imaging use are not well understood. Methods: A cross-sectional national survey was performed of physicians responsible for surveillance of patients with head and neck squamous cell carcinoma (HNSCC). The primary outcome was self-reported use of routine surveillance PET/CT in asymptomatic patients. A secondary outcome was familiarity with guideline recommendations. Using multivariable regression, the impact of guideline familiarity and other physician characteristics on PET/CT use was examined. Results: Of the 502 responders, 79% endorsed ever using PET/CT scans for routine surveillance imaging, and 39% were high imaging users (used PET/CT scans on more than half of their asymptomatic patients); 76% were familiar with the NCCN Clinical Practice Guidelines in Oncology for Head and Neck Cancers recommending against routine surveillance PET/CT scans. Although guideline familiarity was associated with being a low imaging user or a never-user, among those who were familiar with guidelines, 31% were nonetheless high imaging users and 73% endorsed ever using PET/CT scans. In multivariable analysis controlling for physician characteristics, guideline familiarity was the strongest predictor of PET/CT use. Conclusions: Familiarity with the NCCN Guidelines predicts self-reported routine surveillance PET/CT use among physicians who treat patients with HNSCC. However, given the observed variation and high levels of imaging even among physicians who are familiar with the guidelines, further research should examine the reasons physicians choose to use surveillance PET/CT scans.
AB1208 Arthroscopic synovectomy of the knee in patients with juvenile idiopathic arthritis (JIA)
Authors: T. Guszczyn, S. Sierakowski, J. Popko
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Introduction</h3> Arthroscopic synovectomy of the knee is one of the less invasive surgical procedures of the resection of synovium in patients with chronic synovial hypertrophy inflammation. Some rheumatologists doubt in the effectiveness of such procedure. In their opinion the JIA is a systemic disease whereas the synovectomy is restricted to selected joints only. <h3>Objectives</h3> It was decided to present the results of our synovectomy procedure and to evaluate the effectiveness of this method during 6,5 year observation. <h3>Material and methods</h3> 15 patients of the age 7-23 (mean 15.5) with JIA (10 girls and 5 boys) were submitted to arthroscopic synovectomy in the Department of Pediatric Orthopedics and Traumatology, Medical University of Bialystok (in 2001-2007). In one case both knee joints were operated. In all cases the disease process took about 3 years. <h3>Results</h3> The most important symptoms of recovery was significant reduction of the oedema in the joint area and a decrease in the volume of intraarticular exudate. Unfortunately, the procedure did not improve the range of motion. In a short periodof observation was significantreduction of pain. <h3>Conclusions</h3> It seems that the surgical reduction in the volume of intraarticular inflammatory tissue evokes the formation of new synovium with lower metabolic activity. Such a newly formed tissue does not exert a disruptive role on the articular cartilage. The newly formed synovium allows better penetration of antirheumatic drugs and increases the effectiveness of treatment. <h3>Disclosure of Interest</h3> None Declared
RELATIONSHIP BETWEEN VESSEL SIZE, PLATELET REACTIVITY, AND STENT THROMBOSIS AFTER DRUG-ELUTING STENT PERCUTANEOUS CORONARY ARTERY INTERVENTION
Authors: Bjorn Redfors, Rushad K. Dordi, Tullio Palmerini, Gennaro Giustino, Girma Ayele, Adriano Caixeta, Ajay Kirtane, Roxana Mehran, Gregg Stone, Philippe Genereux
Journal: Journal of the American College of Cardiology (2016)
<i>Candida albicans</i>Endocarditis Successfully Treated with Amphotericin B
Authors: Frank W. Kroetz, James J. Leonard, Charles R. Everett
Journal: New England Journal of Medicine (1962)

MONILIAL endocarditis is almost uniformly fatal. The case reported below was successfully treated with amphotericin B. The patient has remained well in the twenty-one months since the termination of the amphotericin B therapy.In 1958 Merchant et al.,1 in a review of the literature, found 11 proved cases of monilial endocarditis, all of which ended fatally.2 3 4 5 6 7 8 9 10 11 12 Twelve additional fatal cases have been reported since this review.13 14 15 16 17 18 Louria and Dineen17 described a case of disseminated moniliasis with endocarditis that was successfully treated with amphotericin B. Their patient underwent a series of laparotomies and was chronically ill. During recovery from surgery widespread . . .
SP0157 Infection and Rheumatic Disease
Authors: D. Symmons
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> This lecture will review the literature from the past 12 months which relates to infection and rheumatic disease. The principal areas covered will be (i) infection (e.g. porphyromonas gingivalis) as a risk factor for the development of arthritis; (ii) infection as a co-morbidity of rheumatic disease and (iii) infection as a complication of treatment (which may be surgical or medical). Most of the published literature on infection as a complication of treatment relates to fungal infections, hepatitis B and C, and tuberculosis occurring in patients receiving biologic therapy for rheumatoid arthritis. The literature on infection following surgery relates to infection of prosthetic joints. <h3>Disclosure of Interest</h3> None Declared
Successful treatment of cervical esophageal obstruction using combined antegrade and retrograde dilation with an endoscopic ultrasound needle and fully covered stent
Authors: B. Ancrile, A. Mathew, M. Moyer
Journal: Endoscopy (2011)

While complete esophageal obstruction is a technically challenging problem, the combined antegrade and retrograde dilation (CARD) procedure provides an endoscopic treatment option for these obstructions [1] [2] [3], and the addition of an endoscopic ultrasound (EUS) needle increases the speed and convenience of the procedure [4] [5]. Here we describe use of this technique for the successful treatment of a long cervical esophageal occlusion by using flexible endoscopes and a fully covered removable stent.
Abstract 525: ADAM-9 expression in gastric cancer and its association with invasiveness
Authors: Jeong Min Kim, Eun Jeong Yu, Jae Joon Jung, Tae Soo Kim, Sun Young Rha, Joong Bae Ahn, Jung Ryun Ahn, Chan Kim, Hyun Cheol Chung, Jae Kyung Roh, Hei-Cheul Jeung
Journal: Cancer Research (2010)

Abstract The ADAMs (a disintegrin and metalloproteinase) comprise a family of multidomain transmembrane and secreted proteins. Accumulating evidence associates an increased expression of individual ADAM family members with various types of cancer including prostate, breast, skin and lung cancers. However, little is known about its role in gastric cancer. Herein, we investigated the expression of ADAM-9 in gastric cancer, and its implication as a potential therapeutic target for anti-metastaasis therapy. First, we evaluated the expression of ADAM-9 on protein by immunoblotting and transcript level in 24 gastric cancer cell lines by RT-PCR. ADAM-9 protease activity was also measured using ADAM-9 fluorogenic substrate (R&amp;D systems, Minneapolis, MN, USA). We then conducted invasion assay using transwell coated with matrigel in the presence or absence of ADAM-9-specific inhibiting antibody (kindly supplied from Raven Biotechnologies, Inc., South San Francisco, CA). The mRNA expression of ADAM-9 was observed in all the gastric cancer cell lines while the protein expressions of pro- and active-form and protease activities were variable. We selected the cell lines of high baseline ADAM-9 expression (SNU-638, MKN-28 and AGS) and of low baseline expression (SNU-216, MKN-1 and HS-746T) to continue further experiment. Baseline level of ADAM-9 is little correlated with invasion activity though matrigel. Treatment of anti-ADAM-9 antibody does not influence the cytotoxicity. However, it reduced its protease activity and invasiveness, which was dependent on baseline ADAM-9 activity. Actually, protease activity reduced 64.5±0.3% when the specific antibody to ADAM-9 was treated to high expressed cell lines, but 9.6±0.4% were decreased in low expressed cell lines at the 20ug/ml of the antibody. Anti-ADAM-9 antibody inhibited the invasion activity dose dependently, and its effect was more prominent in high ADAM-9-expressing cell lines (67.7±1.9% vs 5.9±4.3% at the 20 ug/ml antibody). Anti-ADAM-9 treatment did not influence on the cell-matrix adhesion, which implies this anti-invasive effect is through its inhibition of protease function. In the hypoxic condition (1% oxygen), invasion was increased along with elevation of both active form of ADAM-9 and its protease activity, suggesting that increased ADAM-9 could have a role of enhancing invasiveness of gastric cancer. To conclude, we presented that ADAM-9 has a role in invasiveness of gastric cancer and would be one of the putative targets for anti-metastasis therapy. This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 525.
Abstract 1611: Transcriptome analyses of the tumor cell line resistant to anti-VEGF therapy.
Authors: Dong Li, Kun Xie, Guitao Ding, Hongwen Li, Xuejing Yao, Cizhong Jiang, Jianmin Fang
Journal: Cancer Research (2013)

Abstract Despite overt clinical success of anti-VEGF (vascular endothelial growth factor) agents, such as Avastin, for cancer patients, increasing evidence shows that prolonged treatment of anti-VEGF therapy results in tumor resistance. In order to understand how tumor cells become resistant to anti-VEGF therapy, we developed a mouse Lewis lung carcinoma (LLC) cell line, which was resistant to a potent VEGF blocker, VEGF-Trap. The cell line was established through five rounds of VEGF-Trap treatment and selection in vivo. In each round, C57BL/6 mice were inoculated with LLC cells and subjected to VEGF-Trap or PBS treatment. Tumors grown from treated mice were harvested and the isolated cells were injected to a new batch of mice for the next round of treatment. It was found that tumor cells became insensitive to VEGF-Trap in vivo after five rounds of VEGF-Trap treatment, i.e., VEGF-Trap no longer inhibited tumor growth. In contrast, VEGF-Trap remained efficacious to the LLC cells which underwent five passages in mice but treated with PBS. The resistance phenotype was maintained in LLC cells after the tumor cells were expanded for a number of passages in vitro, indicating that the resistance was due to inherited alterations in tumor cells. To gain insights into the molecular mechanism underlying the resistance to anti-VEGF therapy, we compared transcriptome profiles of the resistant and non-resistant tumor cells using mRNA-seq. The next generation sequencing reads were aligned to mouse genome; gene transcripts were assembled and calculated for relative abundance for individual gene. Results showed that 644 genes were differentially expressed with statistically significances, 317 up-regulated and 327 down-regulated in the resistant tumor cells. Interestingly, VEGF-C was significantly up-regulated in the resistant tumor cells (fold change = 4.91), which was further verified by real-time PCR analysis. Given the stimulatory effects of VEGF-C on both angiogenesis and lymphatic angiogenesis, it is possible that VEGF-C over-expression plays a role in the development of LLC tumor resistance to anti-VEGF therapy. Citation Format: Dong Li, Kun Xie, Guitao Ding, Hongwen Li, Xuejing Yao, Cizhong Jiang, Jianmin Fang. Transcriptome analyses of the tumor cell line resistant to anti-VEGF therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1611. doi:10.1158/1538-7445.AM2013-1611
Incidental Detection of an Abdominal Aortic Aneurysm During Evaluation of Gastrointestinal Bleeding with Tc-99m-Tagged Erythrocytes
Authors: Paulo S Duarte, Hongming Zhuang, Flavia Aldighieri, Nasrin Ghesani, Abass Alavi
Journal: Clinical Nuclear Medicine (2002)

DUARTE, PAULO S. M.D.*; ZHUANG, HONGMING M.D., Ph.D.†; ALDIGHIERI, FLAVIA B.Sc.*; GHESANI, NASRIN M.D.†; ALAVI, ABASS M.D.† Author Information
Abstract 1401: Dietary selenium and metastasis in a mouse model
Authors: Andrea M. Mastro, Yu-Chi Chen, Donna M. Sosnoski, K Sandeep Prabhu
Journal: Cancer Research (2012)

Abstract The skeleton is a common site for breast cancer metastasis. Once breast cancer cells enter the bone microenvironment, they alter the homeostasis of the bone remodeling system in favor of osteoclasts, which results in osteolysis. Breast cancer cells induce an osteoblast inflammatory response resulting in the production of IL-6, IL-8, MCP-1, and COX-2, known to promote osteoclastogenesis. Therefore, down-regulation of the inflammatory response of the osteoblasts brought about by breast cancer cells may reduce the activation of osteoclasts and decrease osteolysis. IL-6, MCP-1, COX-2 are regulated by a common transcription factor, NF-κB which is sensitive to intracellular redox status; its activation can be inhibited by cellular antioxidant enzymes. Two major antioxidant enzymes, glutathione peroxidase and thioredoxin reductase are selenoenzymes. Their dependence on selenium (Se) offers a way to increase their expression and activity, block NF-κB activation and thus inhibit the expression of its target genes. The hypothesis was that inhibition of NF-κB through dietary selenium would prevent the osteoblast inflammatory response and metastasis. To test the effect of dietary selenium in breast cancer progression, one of five diets: three selenium supplementation diets (sodium selenite, selenomethionine, and methylseleninic acid) or a selenium-deficient or a selenium adequate diet was fed to Balb/c mice for 3 months before inoculation of a metastatic breast cancer cell line 4T1.2luc into the mammary gland. The growth and metastasis of the tumors were followed by IVIS imaging. After 4 weeks, organs were collected and prepared for Q-PCR analysis of the luciferase gene as an indicator of metastatic burden. There was no significant difference in the development or growth of the primary breast tumor and the metastatic patterns between mice receiving the selenium-deficient or selenium-adequate diets. On the other hand, selenium supplementation diets were shown to affect breast cancer progression differently. Mice with sodium selenite supplementation developed the most metastasis (15/15) and showed higher incidence of breast cancer kidney and bone metastasis. The selenomethionine supplementation diet (3ppm) reduced breast cancer primary tumor growth and decreased overall tumor burden in major organs, such as lung, liver, kidney and femur. Taken together, this study showed that dietary selenium affected tumor growth and metastasis and that the selenomethionine supplementation diet offered the most protective effect on breast cancer progression. Support: American Institute for Cancer Research with supplemental support from the National Foundation for Cancer Research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1401. doi:1538-7445.AM2012-1401
1341 ARE CURRENT NORMAL RANGES SET TOO HIGH? PREVALENCE OF ABNORMAL LIVER TRANSAMINASES IN A LARGE POPULATION-BASED COHORT OF THE RUHR AREA
Authors: J. Kälsch, H. Kälsch, D. Heider, J.-P. Sowa, L.P. Bechmann, S. Moebus, U. Slomiany, R. Erbel, K.-H. Jöckel, G. Gerken, A. Canbay
Journal: Journal of Hepatology (2013)
EUS-FNA of a portal vein thrombosis in a patient with a hidden hepatocellular carcinoma: confirmation technique after contrast-enhanced ultrasound
Authors: Miguel Moreno, Antonio Gimeno-García, María Corriente, David Nicolás-Pérez, Alejandro Brito-García, Candelaria García-Castro, Enrique Quintero
Journal: Endoscopy (2014)

The differentiation of a malignant from a benign portal vein thrombosis is of paramount importance in the management of a patient with cirrhosis and a potentially curable hepatocellular carcinoma. Contrast-enhanced ultrasound has led to significant progress in the diagnosis of malignant portal vein thrombosis [1]. More invasive techniques, such as transabdominal ultrasound-guided fine-needle aspiration cytology (TUS-FNA), have proved to be feasible in this setting, but they are not without complications and are sometimes technically not possible [1]. The use of endoscopic ultrasound-guided fine-needle aspiration cytology (EUS-FNA) has been rarely reported in this setting [2] [3], but in no case after inconclusive results of contrast-enhanced ultrasound.